| Pair Name | Solamargine, Cisplatin | ||
| Phytochemical Name | Solamargine (PubChem CID: 73611 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Solamargine, Cisplatin | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | SHH | hsa6469 |
| Down-regulation | Expression | CCND1 | hsa595 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| In Vitro Model | NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 |
| NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
| Result | Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids | |||
| No. | Title | Href |
|---|---|---|
| 1 | Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. Front Pharmacol. 2022 Aug 10;13:802168. doi: 10.3389/fphar.2022.802168. | Click |
